ADVAN-Z: Efavirenz vs Boosted Indinavir in Advanced HIV

Phase 4, randomised, open-label trial of efavirenz and indinavir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Hospital Clínic de Barcelona. Primary endpoints: Proportion of patients with VL below 20 copies/ml at 24 months and Proportion of patients with a CD4 count higher than 200 cells/ml at 24 months. Status: completed.